Ann: Veyonda and Radiotherapy Delivers Clinical Benefits, page-6

Looks reasonably promising to see reduction in PSA and tumour size, although we don't know how much is attributable purely to radiotherapy.

Disappointing to not see any full abscopal responses, which indicates this drug won't be the blockbuster some of us once dared to dream it might be. Best hope is probably for it to stop progression in a useful percentage of late-stage cases. Because it targets stem cells, I have hopes that this effect could be quite enduring. A drug that generally won't eliminate cancer, but stops it progressing, would still be of considerable value. 

Looking forward with interest to the 24 week results. If a reasonable proportion of patients remain progression free at that stage, then I'll start to get excited, because it's much less likely to be radiotherapy alone that produces a sustained effect.